<DOC>
	<DOCNO>NCT03006770</DOCNO>
	<brief_summary>This randomize , placebo-controlled , parallel group , multicenter , Phase III study.The study aim evaluate Efficacy , Tolerability Safety Intramuscular Injections PLX PAD Treatment Subjects Critical Limb Ischemia ( CLI ) Minor Tissue Loss ( Rutherford Category 5 ) Unsuitable Revascularization .</brief_summary>
	<brief_title>Efficacy , Tolerability Safety Intramuscular Injections PLX PAD Treatment Subjects With Critical Limb Ischemia ( CLI ) With Minor Tissue Loss Who Are Unsuitable Revascularization</brief_title>
	<detailed_description />
	<mesh_term>Ischemia</mesh_term>
	<criteria>1 . Adult male female subject age 4599 year age . 2 . CLI , minor tissue loss ( Rutherford Category 5 ) 3 . Ankle pressure ( AP ) ≤70 mmHg TP ≤50 mmHg index leg . If subject ABI &gt; 1.4 TP measureable , inclusion may base TcPO2 ≤30 mmHg . 4 . Subject unsuitable revascularization ( method ) index leg . 5 . Ischemic wound index leg stable least 2 week . 6 . Ischemic wound index leg without tendon bone exposure . 7 . Under treatment cardiovascular risk factor : hypertension , hyperlipidemia , diabetes , accordance applicable guideline . Concomitant therapy statin antiplatelet agent least 2 week prior randomization . 8 . Women childbearing potential must negative serum pregnancy test screening must willing use least one reliable form birth control throughout study . 9 . Signed informed consent form . 1 . Nonatherosclerotic PAD ( e.g . Buerger 's disease ) . 2 . CLI major tissue loss ( Rutherford Category 6 ) either leg . 3 . Evidence active infection ( e.g. , cellulitis , osteomyelitis ) . 4 . Subject undergone surgical/endovascular revascularization major/minor amputation , le 1 month prior screen . 5 . Planned potential need major/minor amputation revascularization within 1 month study entry upon investigator 's judgment . 6 . Aortoiliac stenosis common femoral artery stenosis ≥70 % , otherwise inadequate inflow leg . 7 . Life expectancy le 6 month . 8 . Transient ischemic attack ( TIA ) / stroke acute myocardial infarction/unstable angina within 3 month prior screen . 9 . Severe congestive heart failure symptom ( New York Heart Association [ NYHA ] Stage IV ) . 10 . Uncontrolled severe hypertension . 11 . Diabetes mellitus HbA1c &gt; 10 % . 12 . Current history proliferative retinopathy . 13 . Known Hepatitis B virus Hepatitis C virus acquire immunodeficiency syndrome ( AIDS ) infection . 14 . Subjects international normalize ratio ( INR ) &gt; 2.5 . 15 . Subject renal replacement therapy Creatinine Clearance &lt; 30 ml/min . 16 . Subject currently enrol , yet complete period least 30 day since end another investigational device drug trial ( ) . 17 . Known allergy follow : DMSO , human serum albumin , bovine serum albumin . 18 . History allergic/hypersensitivity reaction substance require hospitalization and/or treatment IV steroids/epinephrine . 19 . Pulmonary disease require supplemental oxygen treatment daily basis . 20 . Active malignancy history malignancy within 5 year prior study entry . 21 . In opinion investigator , subject unsuitable participating study . 22 . Inability understand provide inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>